Fertility preservation in ovarian cancer patients

Gynecol Endocrinol. 2021 Jun;37(6):483-489. doi: 10.1080/09513590.2021.1872534. Epub 2021 Jan 27.

Abstract

Ovarian cancer is more frequent in post-menopausal women, however it can also occur in young premenopausal women. After diagnosis and cancer staging, health care providers should address the possibility of infertility and might offer fertility preservation options. Chemotherapy, frequently used when treating ovarian cancer, has proven to cause extensive ovarian damage. Standard surgery may be aggressive and the recurrence risk may not be relevant enough to opt for these approaches. Fertility sparing surgery has been progressively accepted and many alternative surgical approaches have proven to be successful in both cancer treatment, fertility preservation and low recurrence rates. Though there are several techniques available for fertility preservation in cancer patients, when dealing with ovarian cancer patients, oocyte and embryo cryopreservation are the only suitable. Ovarian tissue cryopreservation has been largely studied, but no data on ovarian cancer patients exist, due to the risk of reimplanting cancer cells.

Keywords: GnRH; Ovarian neoplasms; chemotherapy; fertility preservation; organ sparing treatments.

Publication types

  • Review

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Carcinoma, Ovarian Epithelial / pathology
  • Carcinoma, Ovarian Epithelial / therapy*
  • Cryopreservation / methods
  • Embryo, Mammalian
  • Female
  • Fertility Preservation / methods*
  • Humans
  • Infertility, Female / chemically induced
  • Infertility, Female / prevention & control
  • Neoplasm Recurrence, Local / prevention & control
  • Oocytes
  • Ovarian Neoplasms / pathology
  • Ovarian Neoplasms / therapy*
  • Ovary